Aveanna Healthcare (NASDAQ:AVAH) Insider Edwin Reisz Sells 50,000 Shares

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) insider Edwin Reisz sold 50,000 shares of the company’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $11.50, for a total value of $575,000.00. Following the completion of the sale, the insider owned 1,397,897 shares of the company’s stock, valued at approximately $16,075,815.50. The trade was a 3.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Aveanna Healthcare Trading Up 4.1%

Shares of NASDAQ:AVAH opened at $13.70 on Tuesday. The stock has a 50 day moving average of $9.71 and a 200 day moving average of $7.95. The company has a market cap of $2.99 billion, a PE ratio of 11.14, a price-to-earnings-growth ratio of 0.92 and a beta of 1.90. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 4.47. Aveanna Healthcare Holdings Inc. has a 12-month low of $5.93 and a 12-month high of $13.98.

Aveanna Healthcare (NASDAQ:AVAH) last issued its quarterly earnings results on Thursday, August 13th. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.05. The business had revenue of $670.48 million for the quarter, compared to the consensus estimate of $638.61 million. Aveanna Healthcare had a net margin of 10.56% and a return on equity of 80.70%. As a group, equities research analysts expect that Aveanna Healthcare Holdings Inc. will post 0.68 EPS for the current year.

Institutional Trading of Aveanna Healthcare

Several hedge funds have recently bought and sold shares of AVAH. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Aveanna Healthcare by 252.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,351 shares of the company’s stock valued at $27,000 after purchasing an additional 2,400 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of Aveanna Healthcare in the second quarter worth about $43,000. Summit Securities Group LLC purchased a new stake in shares of Aveanna Healthcare in the first quarter worth about $53,000. Oxford Asset Management LLP purchased a new stake in shares of Aveanna Healthcare in the second quarter worth about $64,000. Finally, C M Bidwell & Associates Ltd. bought a new position in Aveanna Healthcare during the second quarter valued at approximately $69,000. Hedge funds and other institutional investors own 87.96% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on AVAH. Wall Street Zen downgraded shares of Aveanna Healthcare from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 15th. Truist Financial raised their price target on Aveanna Healthcare from $11.00 to $15.00 and gave the company a “hold” rating in a report on Monday. Royal Bank Of Canada boosted their price objective on Aveanna Healthcare from $10.00 to $16.00 and gave the company an “outperform” rating in a research report on Monday. Raymond James Financial upped their price objective on Aveanna Healthcare from $13.00 to $15.00 and gave the stock a “strong-buy” rating in a research note on Friday, August 14th. Finally, Barclays lifted their target price on Aveanna Healthcare from $9.00 to $9.50 and gave the company an “overweight” rating in a research note on Thursday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Aveanna Healthcare presently has an average rating of “Moderate Buy” and a consensus target price of $12.89.

Trending Headlines about Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Royal Bank of Canada raised its price target from $10 to $16 and upgraded its rating to “outperform,” implying additional upside from the stock’s recent trading level. Benzinga analyst coverage
• Positive Sentiment: Truist Financial lifted its price target from $11 to $15 while maintaining a “hold” rating. The higher target reflects improved valuation expectations, even though Truist remains cautious on the shares. Benzinga analyst coverage
• Negative Sentiment: Insiders and major shareholders disclosed approximately 48.6 million shares of sales at an average price of $11.50, worth roughly $558.5 million. Sellers included Paul R. Vigano, Robert M. Williams Jr., and J.H. Whitney Equity Partners V, as well as CEO Jeff Shaner, director Rodney D. Windley, and insider Edwin C. Reisz. Although the sellers retained sizable positions, the volume of stock coming to market may pressure AVAH and raise questions about shareholder confidence. SEC insider transaction filing

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.